Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Shah on Cellular Therapies for Patients With Myeloma

Nina Shah, MD
Published: Monday, Feb 12, 2018



Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Comprehensive Cancer Center, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in myeloma.

There are many existing cellular therapies, specifically engineered T-cell receptors that target NY-ESO-1. There are several clinical trials exploring this, one of which UCSF will be participating in. In addition, the updated results of CAR T-cell therapy, presented at the 2017 ASH Annual Meeting, showed response rates of 94% in those who were evaluable. Similarly, 9 out of 10 patients had minimal residual disease (MRD) negativity.

There is much excitement that patients who have been heavily pretreated, specifically a median of 7 lines of treatment, can reach MRD negativity. UCSF will soon open several respective trials to further explore the use of CAR T cells in myeloma.
 


Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco (UCSF) Helen Diller Comprehensive Cancer Center, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in myeloma.

There are many existing cellular therapies, specifically engineered T-cell receptors that target NY-ESO-1. There are several clinical trials exploring this, one of which UCSF will be participating in. In addition, the updated results of CAR T-cell therapy, presented at the 2017 ASH Annual Meeting, showed response rates of 94% in those who were evaluable. Similarly, 9 out of 10 patients had minimal residual disease (MRD) negativity.

There is much excitement that patients who have been heavily pretreated, specifically a median of 7 lines of treatment, can reach MRD negativity. UCSF will soon open several respective trials to further explore the use of CAR T cells in myeloma.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x